Wednesday, July 15, 2015
Zogenix, a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, has appointed Gail M. Farfel, Ph.D., executive vice president and chief development officer, and Thierry Darcis, M.D., M.B.A., executive vice president and general manager, Europe.
ERT, a global provider of patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, has appointed Steve Nuckols executive vice president and chief commercial officer. As chief commercial officer, Nuckols will be responsible for all global business development activities within ERT, with primary focus on ensuring ERT’s products and services best meet the needs of its global pharmaceutical customers.
Brian A. Leuthner, Edge Therapeutics’ CEO, president and co-founder, has received the EY Entrepreneur of the Year 2015 New Jersey Region Award in the Pharmaceutical & Diagnostic Private Companies category. He was selected by an independent judging panel comprising previous winners of the award, CEOs, private capital investors and other regional business leaders.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, has appointed Dr. Hugh Sampson chief scientific officer. In partnership with Dr. Dupont, chairman of the company’s scientific advisory board, Sampson will lead DBV’s research team, pursuing new Viaskin applications for the treatment of food allergies, while also supporting the company’s clinical development teams.
Department of Health and Human Services Secretary Sylvia M. Burwell has announced the seven winners of the 2015 HHS Innovates Awards. This annual award program, in its eighth round, recognizes creative solutions developed by HHS employees in response to some of the nation’s most challenging problems in health, health care and government. Winners this year reflected a number of collaborative innovation projects representing seven different operating divisions.
The National Institutes of Health has announced the appointment of eight individuals to the NIH Council of Councils. The council was established to advise the NIH director on policies and activities of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), including making recommendations on research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis or would otherwise benefit from strategic planning and coordination.